Anthony is Professor of Surgical Pathology at the University of Sydney and current chairman of the Australian Pancreatic Cancer Genome Initiative. He graduated in medicine from the University of Sydney in 1997. He completed his specialty training in surgical pathology (FRCPA) in 2005 and since then has divided his time between diagnostic pathology as a senior staff specialist at Royal North Shore Hospital and medical research, both at the Garvan Institute of Medical Research and the University of Sydney. His research has concentrated on translating advances made in the understanding of cancer at the basic science or molecular level into diagnostic tests which can be applied in the routine surgical pathology laboratory on patient biopsy specimens. He has authored more than 250 peer reviewed publications and was a member of the World Health Organisation (WHO) consensus committee which recently finalized the newly released WHO 2017 classification of endocrine neoplasia.
Awards and Honours
Ramzi Cotran you Investigator Award in 2017 by the United States and Canadian Academy of Pathology (USCAP)
John Loewenthal Medal and a higher doctorate by publication (MD) from the University of Sydney in 2011
NSW Premier’s Award for Excellence in Translational Cancer Research in 2013
Sir Zelman Cowen Universities Prize for discovery in Medical Research in 2014
FFsc FRCPA 2011
Doctor of Medicine (University of Sydney) 2011
Top 5 publications in the last 5 years:
- Gill et al Am J Surg Pathol 2014 38:1588-602 (supported by Gill et al N Eng J Med 2011 364;9:885-886; Gill et al Am J Surg Pathol 2011 35:1578-1585); – His description of a new class of renal neoplasia driven by germline mutations in SDHx has led to a new class of renal carcinoma (succinate dehydrogenase deficient renal carcinoma) being recognised as a ‘new’ and distinct type of kidney cancer by the World Health Organization (WHO). In recognition of his contribution in this area, the WHO invited him to first author the inaugural WHO blue book chapter on SDH deficient renal cancer.
- Biankin et al Nature 2012 491:399-405, Waddell et al Nature 2015;518:495-501; Bailey et al Nature 2016;531:47-52, Scarpa et al Nature (in print 2017) – Initially as the lead pathologist on the International Cancer Genome Consortium's (ICGC) project to sequence the pancreatic cancer genome and subsequently as the chairman of the APGI, Prof Gill's contribution has pivotal in these landmark publications which define the major pathways in pancreatic carcinogenesis and neuroendocrine tumorigenesis.
- Toon et al Am J Surg Pathol 2013 37:1592-1602 and Toon et al Modern Pathology 2014 27:644-50 (Gill Senior author) – As the senior author on these two publications Prof Gill developed and then validated a new screening algorithm for Lynch Syndrome presenting with colorectal carcinoma based on a combination of immunohistochemistry for mismatch repair proteins and BRAFV600E. Importantly this algorithm has the added benefit of being an extremely strong prognostic marker in non-Lynch syndrome related colon cancer. A/Prof Gill's work has lead to this approach beginning to be used routinely in many centres around the world and the combination of BRAF and MMR IHC is rapidly become the first prognostic marker for colorectal carcinoma actually being deployed in the routine clinical setting.
- Trpkov et al Am J Surg Pathol 2016;40:865–875 (Gill Senior author) – As the senior scientific author on this publication, Prof Gill drew together an international collaboration of Anatomical Pathologists to definitively describe another ‘new’ type of renal carcinoma now known as ‘fumarate hydratase deficient renal carcinoma’.
- Harrison et al Am J Surg Pathol 2016; 40:599–607(Gill Senior author) – As the senior scientific author on this publication, Prof Gill definite the clinical, morphological and genetic features of a unique subtype of uterine leiomyoma now known as fumarate hydratase deficient uterine leiomyoma.